Competitive Landscape: Leading Companies and New Entrants in the Prostate-Specific Membrane Antigen (PSMA) Theranostic Kits Market

The prostate-specific membrane antigen (PSMA) theranostic kits market is poised for significant expansion in the coming years, driven by advancements in personalized medicine and diagnostic technologies. This evolving sector is witnessing a surge in demand as healthcare providers seek more effective and targeted options for prostate cancer detection and treatment. Below is an in-depth look at the market's size, key players, important trends, and major segments shaping its growth.

Projected Market Value and Growth Trajectory for PSMA Theranostic Kits
The PSMA theranostic kits market is anticipated to grow substantially, reaching a market size of $1.99 billion by 2030. This growth reflects a compound annual growth rate (CAGR) of 13.5% over the forecast period. Factors fueling this expansion include rising demand for personalized cancer therapies, increased investments in theranostic solutions, the development of nuclear medicine infrastructure, and a greater use of precision oncology diagnostics. Additionally, there is a growing wave of regulatory approvals supporting targeted therapies. Emerging trends such as the wider adoption of radioligand therapies, enhanced integration of diagnostic imaging with therapeutics, and a focus on companion diagnostics are expected to further propel this market forward.

Download a free report of the prostate-specific membrane antigen (psma) theranostic kits market report:
https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Driving Factors Behind the Surge in PSMA Theranostic Kits Demand
One significant driver of growth is the escalating need for personalized treatment approaches tailored to individual cancer profiles. As oncologists emphasize precision medicine, theranostic kits that combine diagnostics and therapy become essential tools in effective treatment planning.
Another key influence is the expansion of nuclear medicine facilities and infrastructure worldwide. This development allows for broader access to advanced diagnostic and therapeutic options, making PSMA kits increasingly available in diverse healthcare settings, which encourages market growth.

Key Companies Leading the PSMA Theranostic Kits Market
The competitive landscape of the PSMA theranostic kits market features several prominent firms, including Cyclotek (Aust) Pty Ltd, Telix Pharmaceuticals Ltd, Curium Pharma, SOFIE Biosciences Inc., Lantheus Holdings Inc., Eckert & Ziegler SE, NorthStar Medical Radioisotopes, Isotopia Molecular Imaging Ltd, ITM Isotope Technologies Munich SE, AdvanCell Pty Ltd, Alpha?9 Theranostics Inc., ABX Advanced Biochemical Compounds GmbH, Clarity Pharmaceuticals Ltd, Ariceum Therapeutics GmbH, RadioMedix Inc., Scintomics GmbH, Novartis AG, Bayer AG, POINT Biopharma Inc., and Blue Earth Diagnostics.
A notable recent event in the market was the acquisition of Theragnostics Ltd. by Ariceum Therapeutics GmbH in June 2023. This German biotech company aims to bolster its expertise in PSMA-targeted theranostic kits and broaden its prostate cancer imaging product portfolio. Theragnostics Ltd., based in the UK, specializes in PSMA-targeted diagnostic kits such as 68Ga THP PSMA, designed specifically for prostate cancer imaging.

View the full prostate-specific membrane antigen (psma) theranostic kits market report:
https://www.thebusinessresearchcompany.com/report/global-prostate-specific-membrane-antigen-psma-theranostic-kits-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Emerging Trends and Innovations Shaping the PSMA Theranostic Kits Industry
Companies in this sector are increasingly focusing on developing innovative PSMA-targeted radioligand kits that address the rising demand for precision oncology. These kits combine a ligand specific to the Prostate-Specific Membrane Antigen with a radioactive isotope, enabling both diagnostic imaging and targeted therapy for prostate cancer.
For example, in March 2025, Telix Pharmaceuticals Limited from Australia launched Illuccix, a novel kit designed to prepare Gallium-68 gozetotide injection. This kit facilitates on-site radionuclide labeling just before injection, optimizing PET imaging of PSMA-positive prostate cancer lesions. Its features include a ready-to-use format, targeted disease specificity, rapid imaging capacity, and seamless compatibility with theranostic workflows. Illuccix supports improved detection of metastatic lesions, assists treatment planning, and aids in therapy monitoring, marking a significant advancement over traditional imaging or non-targeted treatments.

Detailed Segmentation Driving the PSMA Theranostic Kits Market
The market is segmented by product type into Diagnostic Kits, Therapeutic Kits, and Combined Theranostic Kits. It is further broken down by application, primarily prostate cancer and other cancers, and by end-user categories such as hospitals, diagnostic centers, research institutes, specialty clinics, and others.
Within diagnostic kits, subcategories include PSMA Positron Emission Tomography (PET) Imaging Kits, Single Photon Emission Computed Tomography (SPECT) Imaging Kits, Companion Diagnostic Kits, and Liquid Biopsy Kits. Therapeutic kits are classified into Radioligand Therapy Kits, Antibody-Based Therapy Kits, Peptide-Based Therapy Kits, and Small Molecule Therapy Kits. Combined theranostic kits comprise Integrated Imaging and Therapy Kits, Dual Function Radiopharmaceutical Kits, PSMA Ligand-Based Theranostic Kits, and Personalized Treatment Kits designed for tailored patient care.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.